Active Filter(s):
Details:
Company plans to evaluate its amniotic fluid concentrate, AmnioBoost, in patients with acute respiratory distress syndrome (ARDS) caused by coronavirus (COVID-19).
Lead Product(s): Amniotic fluid supplement
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 13, 2020